Sparian Biosciences, Inc. (“Sparian”) submitted testimony to the United States Senate Committee on Finance on the fentanyl public health crisis. Sparian, a clinical-stage biopharmaceutical company, is developing novel therapeutics to…
Read More
Sparian Biosciences, Inc. (“Sparian”) submitted testimony on May 23, 2024, urging the United States Senate to provide the National Institutes of Health (NIH) with the resources to combat the substance…
Read More
SBS-518 is a dual sigma receptor antagonist/dopamine active transporter inhibitor in development for the treatment of stimulant use disorder (e.g., cocaine and methamphetamine) Grant awarded by National Institutes of Health…
Read More
SBS-1000 is the first arylepoxamide agonist for the treatment of pain to receive IND clearance Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics, and analgesic efficacy of SBS-1000…
Read More
SBS-1000 is the first arylepoxamide agonist for the treatment of pain to receive IND clearance Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and analgesic efficacy of SBS-1000…
Read More
